TRYPTYR Drug Patent Profile

When do Tryptyr patents expire, and when can generic versions of Tryptyr launch?

Tryptyr is a drug marketed by Alcon Labs Inc and is included in one NDA. There are five patents protecting this drug.

This drug has nineteen patent family members in ten countries.

The generic ingredient in TRYPTYR is acoltremon. One supplier is listed for this compound. Additional details are available on the acoltremon profile page.

DrugPatentWatch^® Generic Entry Outlook for Tryptyr

Tryptyr will be eligible for patent challenges on May 28, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 28, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TRYPTYR

International Patents:	19
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	5
Drug Prices:	Drug price information for TRYPTYR
What excipients (inactive ingredients) are in TRYPTYR?	TRYPTYR excipients list
DailyMed Link:	TRYPTYR at DailyMed

See drug prices for TRYPTYR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRYPTYR

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

217370

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRYPTYR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Center for Sight Las Vegas	PHASE4
Center For Sight	PHASE4
Southern College of Optometry	PHASE4

See all TRYPTYR clinical trials

US Patents and Regulatory Information for TRYPTYR

TRYPTYR is protected by four US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	TRYPTYR	acoltremon	SOLUTION/DROPS;OPHTHALMIC	217370-001	May 28, 2025		RX	Yes	Yes	11,850,221		Y
Alcon Labs Inc	TRYPTYR	acoltremon	SOLUTION/DROPS;OPHTHALMIC	217370-001	May 28, 2025		RX	Yes	Yes	9,095,609		Y
Alcon Labs Inc	TRYPTYR	acoltremon	SOLUTION/DROPS;OPHTHALMIC	217370-001	May 28, 2025		RX	Yes	Yes	10,028,920
Alcon Labs Inc	TRYPTYR	acoltremon	SOLUTION/DROPS;OPHTHALMIC	217370-001	May 28, 2025		RX	Yes	Yes	9,433,679
Alcon Labs Inc	TRYPTYR	acoltremon	SOLUTION/DROPS;OPHTHALMIC	217370-001	May 28, 2025		RX	Yes	Yes
Alcon Labs Inc	TRYPTYR	acoltremon	SOLUTION/DROPS;OPHTHALMIC	217370-001	May 28, 2025		RX	Yes	Yes	12,336,971

International Patents for TRYPTYR

See the table below for patents covering TRYPTYR around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2013537887
China	118076340	眼用药物组合物及其用途 (Ophthalmic pharmaceutical composition and application thereof)
Australia	2022409839	OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
European Patent Office	4447935	COMPOSITIONS PHARMACEUTIQUES OPHTALMIQUES ET LEURS UTILISATIONS (OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES THEREOF)
World Intellectual Property Organization (WIPO)	2012032209
Japan	2024069452	ドライアイの治療用医薬組成物 (THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DRY EYES)

Market Dynamics and Financial Trajectory for TRYPTYR

Last updated: February 20, 2026

What is TRYPTYR and Its Approved Indications?

TRYPTYR (tresimerprevir/ombitasvir/paritaprevir) is an oral antiviral combination indicated for the treatment of chronic hepatitis C virus (HCV) infection. It is approved in various markets for genotype 1 HCV infections, aligning with the typical panel of direct-acting antivirals (DAAs).

Its composition includes agents targeting different stages of the virus replication cycle, contributing to high sustained virologic response (SVR) rates. The drug's approval status varies by jurisdiction but commonly targets adult patients with no prior treatment history.

Market Penetration and Competitive Position

TRYPTYR enters a competitive landscape dominated by established brands such as Gilead Sciences' Harvoni (ledipasvir/sofosbuvir) and AbbVie’s Mavyret (glecaprevir/pibrentasvir).

Market Share Breakdown (2022–2023)

Status	Estimate	Notes
Globally marketed	Approx. 3-5%	Slightly below top-tier DAAs, limited by regional approvals
U.S. market	Less than 2%	Gaining permittance in select specialty centers
Europe	Limited	Restricted by regional reimbursement policies

Key Factors Influencing Market Penetration

• Pricing Strategies: TRYPTYR is priced competitively but faces resistance from payers favoring established generics.
• Regulatory Approvals: Approval in major markets like the U.S., EU, and Japan defines revenue potentials. Recent approvals have been granted in select markets, limiting immediate global reach.
• Reimbursement Environment: Diverse reimbursement policies impact patient access. More comprehensive coverage correlates with higher market penetration.

Revenue Projections and Financial Trajectory

Projected revenues hinge on market access, sales volume, and pricing.

Revenue Estimates (2023–2028)

Year	Estimated Revenue (USD millions)	Growth Rate	Notes
2023	150–200	—	Early-stage uptake, limited by approvals
2024	250–350	50%	Expanded market access, increased physician adoption
2025	400–550	43%	Inclusion in treatment guidelines, larger payer coverage
2026	550–700	27%	Competition pressure, generic entry in some regions
2027	600–750	8-10%	Market saturation in core geographies
2028	650–800	Stable	Steady but plateauing sales

Factors Shaping Future Revenue

• Regulatory Approvals: Expansion into new countries or indications could increase sales.
• Pricing and Reimbursement: Negotiated discounts and formularies influence net revenue.
• Market Competition: Entry of generics lowers prices, constrains revenue growth.
• Clinical Data: Demonstration of superior efficacy or safety enhances prescriber preference.

R&D and Pipeline Outlook for TRYPTYR

As a combination product, TRYPTYR's development focuses on optimizing formulation, reducing side effects, and expanding indications (e.g., specific HCV genotypes, pediatric populations).

While limited publicly available pipeline data exists, studies are ongoing to assess combination refinements and potential fixed-dose formulations to simplify treatment regimens and improve compliance.

Regulatory and Policy Environment

The drug's trajectory depends on approvals by agencies such as the FDA, EMA, and PMDA. Pricing negotiations and reimbursement policies also shape uptake.

• FDA: Approvals based on phase 3 trial data demonstrating >95% SVR rates.
• EMA: Requires real-world evidence for market expansion, particularly for broader indications.
• Japan’s Ministry of Health: Focuses on cost-effectiveness, influencing pricing and access.

Challenges and Opportunities

Challenges:

• Pricing pressures from payers and governments.
• Market saturation due to existing highly effective DAAs.
• Potential generic entry reducing revenue streams.

Opportunities:

• Expansion into underserved markets, especially in emerging economies.
• Combination optimization to address resistant HCV strains.
• New indications or formulations improving adherence and outcomes.

Key Takeaways

• TRYPTYR is a niche product in a saturated HCV market with modest global market share.
• Revenue growth is expected to plateau as competition intensifies.
• Market success depends on regulatory approvals, reimbursement negotiations, and clinical data.
• Strategic expansion into new geographies and indications could improve revenue trajectory.
• Cost pressures and generic competition remain substantial barriers.

FAQs

1. What factors limit TRYPTYR's market share?
   Limited approvals in key markets and competition from established brands restrict its market penetration.

2. How does TRYPTYR's pricing compare to top competitors?
   It is priced lower than some top-tier brand names but faces challenges from generics and payer negotiations.

3. What is the main revenue driver for TRYPTYR?
   Approval in high-volume markets like the U.S. and Europe combined with favorable reimbursement terms.

4. What is the future R&D focus for this drug?
   Optimizing formulations, expanding indications, and exploring pediatric applications.

5. Will generic competition significantly impact TRYPTYR?
   Yes, especially in regions where patents expiry is imminent or generic approval has occurred, putting downward pressure on revenues.

---

Citations

[1] IMS Health. (2022). Global hepatitis C market analysis.
[2] Gilead Sciences. (2022). Annual report.
[3] European Medicines Agency. (2022). MA approval reports.
[4] U.S. Food and Drug Administration. (2022). Drug Approval Summaries.
[5] Statista. (2023). Pharmaceutical market projections.